Which has the lower trailing P/E, HALO or ICLR?

HALO has the lower trailing P/E: HALO trades at 32.75 and ICLR at 41.49. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, HALO or ICLR?

Over the past five years, HALO grew revenue faster — HALO at a 32.18% CAGR versus ICLR at 20.93%.

Is HALO or ICLR more profitable?

HALO runs the higher net margin — HALO at 24.86% versus ICLR at 3.99%.

How have HALO and ICLR total returns compared?

Over the past 10 years, HALO delivered 24.30% and ICLR delivered 8.07% annualized total return. Past performance doesn't predict future results.

Halozyme Therapeutics, Inc. (HALO) vs ICON Public Limited Company (ICLR)

A side-by-side comparison of Halozyme Therapeutics, Inc. and ICON Public Limited Company across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

HALO

Halozyme Therapeutics, Inc.

$13.01B

$109.70HealthcareDelayed quote: Oct 6, 2026, 9:40 AM EDT

ICLR

ICON Public Limited Company

$13.53B

$176.77HealthcareDelayed quote: Oct 6, 2026, 9:40 AM EDT

Total return — HALO vs ICLR

growth of $100 · dividends reinvested · last 10y

HALO +779.9% (+24.3%/yr)ICLR +121.1% (+8.3%/yr)HALO compounded faster over this window

HALO ICLR

HALO vs ICLR: by the numbers

•ICLR is the larger company ($13.53B vs $13.01B market cap).
•HALO trades at the lower trailing earnings multiple (32.75 vs 41.49 P/E), one valuation lens rather than an overall verdict.
•HALO converts more revenue to profit (24.86% vs 3.99% net margin).
•HALO grew revenue faster over the past five years (32.18% vs 20.93% CAGR).

Metrics side by side

Valuation

Metric	HALO	ICLR
P/E ratio	32.75	41.49
Forward P/E	13.04	16.69
PEG ratio	1.43	N/A
P/S ratio	7.82	1.64
P/B ratio	90.65	1.44
EV / EBITDA	14.22	11.39
FCF yield	6.20%	9.95%

Profitability

Metric	HALO	ICLR
Gross margin	78.18%	21.85%
Operating margin	56.77%	10.15%
Net margin	24.86%	3.99%
ROE	288.13%	3.51%
ROIC	27.42%	4.80%

Growth (annualized)

Metric	HALO	ICLR
Revenue CAGR (5Y)	32.18%	20.93%
EPS CAGR (5Y)	22.68%	-14.23%
FCF CAGR (5Y)	40.08%	22.10%
Total return CAGR (5Y)	22.18%	-8.50%

Frequently asked

Which has the lower trailing P/E, HALO or ICLR?: HALO has the lower trailing P/E: HALO trades at 32.75 and ICLR at 41.49. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, HALO or ICLR?: Over the past five years, HALO grew revenue faster — HALO at a 32.18% CAGR versus ICLR at 20.93%.
Is HALO or ICLR more profitable?: HALO runs the higher net margin — HALO at 24.86% versus ICLR at 3.99%.
How have HALO and ICLR total returns compared?: Over the past 10 years, HALO delivered 24.30% and ICLR delivered 8.07% annualized total return. Past performance doesn't predict future results.

Go deeper

Full HALO analysis Full ICLR analysis Interactive comparison tool

Dig into the metrics

Halozyme Therapeutics P/E ratio ICON Public P/E ratio Halozyme Therapeutics ROE ICON Public ROE Halozyme Therapeutics operating margin ICON Public operating margin Halozyme Therapeutics revenue growth ICON Public revenue growth Halozyme Therapeutics free cash flow ICON Public free cash flow

Halozyme Therapeutics & ICON Public appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.